Developing Selective HDAC Inhibitors
With the emerging roles of histone deacetylase (HDAC) isoforms in tumor biology, the development of isoform selective HDAC inhibitors could be of major importance. A number of compounds including natural and synthesized have been reported to inhibit HDAC activity and most belong to hydroxamic acid class based on suberoylanilide hydroxamic acid (SAHA). SAHA is a non-selective HDAC inhibitor that has recently entered the clinical. We are presently developing isoform selective HDAC inhibitors for advancement as new prostate cancer agents and radiation sensitizing agents.